Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
以 I 期为重点的新型抗癌药物的早期临床试验
基本信息
- 批准号:8628948
- 负责人:
- 金额:$ 25.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-03-18 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:Advanced Malignant NeoplasmAntineoplastic AgentsApplications GrantsBiochemicalBiologicalBiological MarkersCharacteristicsClinicalClinical TrialsColony-Stimulating FactorsDevelopmentDoseDrug KineticsDrug TargetingDrug effect disorderElderlyEnzymesEthnic groupImageLabelLaboratoriesMalignant NeoplasmsMaximum Tolerated DoseMetabolic PathwayMetabolismMolecularMolecular TargetNMR SpectroscopyNational Cancer InstituteOrganPatientsPerformancePharmaceutical PreparationsPharmacodynamicsPharmacogenomicsPharmacologyPhasePhase I Clinical TrialsPhase II Clinical TrialsPhilosophyRaceRadioScheduleScienceTechniquesToxic effectTreatment Protocolsabsorptionantitumor agentbasenovelpatient populationsex
项目摘要
DESCRIPTION (provided by applicant): The premise behind this grant application is that impeccable characterization and understanding of a systemically administered new antineoplastic agent's pharmacology and effect on molecular targets in cancer should allow better clinical utilization of that agent. Determination of clinical toxicities and maximum tolerated dose (MTD) of an agent is no longer sufficient. Ideally, early clinical trials of an investigational agent should define pharmacokinetic (PK) disposition and metabolism, with correlation to pharmacodynamic (PD) manifestations at molecular, cellular, and clinical levels. With this abiding philosophy and hypothesis, performance of scientifically directed phase I trials of promising novel anti-cancer agents available through the National Cancer Institute is warranted. Integrating information regarding the mechanism of action and effect on molecular targets with development of biomarkers in phase I trials is the strategy that will be pursued with the following objectives to : define the toxicities of new antineoplastic agents in patients with advanced cancer; re-define (as necessary)the toxicities and PK of existing anticancer agents administered in combination with molecularly targeted agents, colony stimulating factors and other toxicity-ameliorating agents that may facilitate the exploration of more effective doses and schedules; provide information on the absorption, distribution, metabolism, and elimination of antitumor agents; define treatment regimens for use in phase II trials; establish, based on clinical and pharmacologic characteristics, appropriate phase II doses in special patient populations (e.g., patients with impaired organ function; heavily pretreated patients or geriatric patient populations), explore PK and PD differences based on sex, race, or ethnic group; obtain preliminary information on PK/PD correlations that can then be extended in phase II trials; incorporate basic laboratory and correlative science studies, when possible and appropriate, to enhance the understanding of the biochemical and/or biological mechanisms of drug actions; study the PK and the PD impact of drugs on specific metabolic pathways and molecular targets using non-invasive techniques such as magnetic resonance spectroscopy and nuclear imaging with radio-labeled drugs; and integrate pharmacogenomic studies to characterize differences in relevant drug metabolizing enzymes and drug targets related to toxicity and efficacy.
描述(由申请人提供):本资助申请的前提是对一种系统给药的新型抗肿瘤药物的药理学和对癌症分子靶点的作用进行了无可挑剔的描述和理解,从而使该药物能够更好地用于临床。确定药物的临床毒性和最大耐受剂量(MTD)已不再足够。理想情况下,研究药物的早期临床试验应该确定药代动力学(PK)处置和代谢,并在分子、细胞和临床水平上与药效学(PD)表现相关。有了这个持久的哲学和假设,通过国家癌症研究所提供的有前途的新型抗癌药物的科学指导的I期试验的性能是有保证的。将分子靶点的作用机制和作用信息与I期临床试验中生物标志物的开发相结合,将实现以下目标:确定新型抗肿瘤药物对晚期癌症患者的毒性;重新定义(必要时)现有抗癌药物与分子靶向药物、集落刺激因子和其他可能有助于探索更有效剂量和时间表的毒性改善药物联合使用的毒性和PK;提供抗肿瘤药物的吸收、分布、代谢和消除信息;确定用于II期试验的治疗方案;根据临床和药理学特点,为特殊患者群体(如器官功能受损患者、重度预处理患者或老年患者群体)确定适当的II期剂量,探讨基于性别、种族或族裔群体的PK和PD差异;获得PK/PD相关性的初步信息,然后可以在II期试验中扩展;在可能和适当的情况下,结合基础实验室和相关科学研究,以加强对药物作用的生化和/或生物学机制的理解;利用磁共振波谱和放射性标记药物核成像等非侵入性技术研究药物对特定代谢途径和分子靶点的PK和PD影响;并结合药物基因组学研究,表征与毒性和疗效相关的相关药物代谢酶和药物靶点的差异。
项目成果
期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
- DOI:
- 发表时间:2018-09
- 期刊:
- 影响因子:3.5
- 作者:James J. Lee;E. Chu
- 通讯作者:James J. Lee;E. Chu
Role of PARP inhibitors in cancer biology and therapy.
- DOI:10.2174/092986712802002464
- 发表时间:2012
- 期刊:
- 影响因子:4.1
- 作者:Davar D;Beumer JH;Hamieh L;Tawbi H
- 通讯作者:Tawbi H
Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.
- DOI:10.1007/s00280-013-2296-5
- 发表时间:2013-12
- 期刊:
- 影响因子:3
- 作者:Parise, Robert A.;Beumer, Jan H.;Clausen, Dana M.;Rigatti, Lora H.;Ziegler, Judy A.;Gasparetto, Maura;Smith, Clayton A.;Eiseman, Julie L.
- 通讯作者:Eiseman, Julie L.
PARP inhibitors in breast cancer: BRCA and beyond.
- DOI:
- 发表时间:2011-10
- 期刊:
- 影响因子:3.5
- 作者:J. Rios;S. Puhalla
- 通讯作者:J. Rios;S. Puhalla
Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.
- DOI:10.1007/s00280-012-1980-1
- 发表时间:2013-01
- 期刊:
- 影响因子:3
- 作者:Parise, Robert A.;Anyang, Bean N.;Eiseman, Julie L.;Egorin, Merrill J.;Covey, Joseph M.;Beumer, Jan H.
- 通讯作者:Beumer, Jan H.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD CHU其他文献
EDWARD CHU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD CHU', 18)}}的其他基金
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
对现有 NIH 拨款和合作协议的行政补充(家长管理补充临床试验可选)
- 批准号:
10494563 - 财政年份:2021
- 资助金额:
$ 25.41万 - 项目类别:
NCI ET-CTN with Phase i Emphasis at UPCI
UPCI 重点关注 NCI ET-CTN 第一阶段
- 批准号:
9071388 - 财政年份:2014
- 资助金额:
$ 25.41万 - 项目类别:
NCI ET-CTN with Phase i Emphasis at UPCI
UPCI 重点关注 NCI ET-CTN 第一阶段
- 批准号:
8725328 - 财政年份:2014
- 资助金额:
$ 25.41万 - 项目类别:
NCI ET-CTN with Phase i Emphasis at UPCI
UPCI 重点关注 NCI ET-CTN 第一阶段
- 批准号:
8827308 - 财政年份:2014
- 资助金额:
$ 25.41万 - 项目类别:
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin
新中药PHY906作为艾琳调节剂的临床研究
- 批准号:
9336547 - 财政年份:2011
- 资助金额:
$ 25.41万 - 项目类别:
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin
新中药PHY906作为艾琳调节剂的临床研究
- 批准号:
8555270 - 财政年份:2011
- 资助金额:
$ 25.41万 - 项目类别:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
以 I 期为重点的新型抗癌药物的早期临床试验
- 批准号:
7885768 - 财政年份:2009
- 资助金额:
$ 25.41万 - 项目类别:
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
以 I 期为重点的新型抗癌药物的早期临床试验
- 批准号:
7885774 - 财政年份:2009
- 资助金额:
$ 25.41万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 25.41万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 25.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 25.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 25.41万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 25.41万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 25.41万 - 项目类别: